Lv1
42 积分 2023-12-19 加入
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
21天前
已完结
Head and Neck Cancer: A Review
1个月前
已完结
An evaluation of patritumab deruxtecan for the treatment of EGFR -mutated non-small cell lung cancer
4个月前
已完结
An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions
4个月前
已关闭
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck: A Multicenter, Phase IIa Trial
4个月前
已完结
Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study
5个月前
已完结
Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study
5个月前
已关闭
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
6个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
6个月前
已完结
Navigating the Evolving Landscape of EGFR -Mutated NSCLC
6个月前
已完结
皖公网安备34019202002308
